Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration

Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online  —

SOUTH SAN FRANCISCO, Calif., May 4, 2020 — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced today that two abstracts were published on the 2020 Digestive Disease Week (DDW) site. These abstracts were originally accepted for presentation during the 2020 DDW Conference which was to be held May 2-5 in Chicago, IL.

Both abstracts describe pre-clinical results with a liver-targeted proprietary molecule that enhances Wnt signaling and stimulates tissue regeneration. SWEETS (Surrozen Wnt signal Enhancers Engineered for Tissue Specificity) are antibody-based molecules that enhance Wnt signaling. SWEETS-1, a hepatocyte-targeted SWEETS, is the first proprietary SWEETS molecule to show preclinical proof of concept. The abstracts highlight that SWEETS-1 demonstrated hepatocyte-specific activation of Wnt target genes such as Axin2, stimulated hepatocyte regeneration, and restored liver function as measured by clotting time in a thioacetamide-induced mouse liver injury model.

The first abstract, titled “HEPATOCYTE-TARGETED R-SPONDIN MIMETIC FOR LIVER REGENERATION (Abstract #3346398)” showed that SWEETS-1 enhanced Wnt signaling in a hepatic cell line to a level similar to that induced by R-spondin. SWEETS-1 induced the expression of the Wnt target gene Axin2 in liver only, while R-spondin also induced Wnt signaling in kidney, salivary gland, intestine, heart, and pancreas. Immunofluorescence analysis revealed that SWEETS-1 induced Ki67 positive nuclei specifically in matures hepatocytes.

The second abstract, titled “HEPATOCYTE-TARGETED R-SPONDIN MIMETIC STIMULATES REGENERATION AND RESTORES COAGULATION IN A THIOACETAMIDE-INDUCED LIVER INJURY MODEL (Abstract #3346773)” demonstrated that Wnt family members were elevated in TAA-injured livers, suggesting that SWEETS-1 could be efficacious in liver injury. Indeed, SWEETS-1 induced liver expression of Axin2 to a level similar to that induced by R-spondin in a thioacetamide-induced mouse liver injury model. In addition, SWEETS-1 induced Ki67 positive nuclei in mature hepatocytes. Furthermore, SWEETS-1 treatment restored TAA-impaired clotting time to baseline levels.

“These results suggest that a cell-specific R-spondin-mimetic can selectively stimulate hepatocyte regeneration, differentiation, and function.” said Wen-Chen Yeh, MD, PhD, Chief Scientific Officer at Surrozen.  “We are excited to be able to confirm the relevance of our proprietary SWEETS platform technology and to advance this novel approach to treating liver disease.”

About Wnt Signaling

Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, including liver, intestine, lung, kidney, central nervous system, cochlea, bone, and others. Modulation of Wnt signaling pathways has potential for treatment of degenerative diseases and tissue injuries. There are 19 Wnt ligands (Wnts) in mammals, and they signal through Frizzled receptors 1-10 and co-receptors LRP5 or 6, two families of receptors. Endogenous Wnts bind to multiple Frizzled receptors and are heavily modified post-translationally, making them difficult to manufacture consistently. R-spondin stabilizes Frizzled receptors, enhancing the body’s response to endogenous Wnts.

About Surrozen’s Proprietary Antibody Platforms and Harnessing Wnt Signaling
Since its founding in 2016, Surrozen has developed two proprietary platforms to selectively modulate the Wnt pathway for the potential treatment of injury and disease. Surrozen Wnt-mimetics, also referred to as SWAP (Surrozen Wnt signal Activating Proteins), are bi-specific full-length human (IgG) antibodies that directly activate the canonical Wnt signaling pathway in target tissue. Surrozen R-spondin-mimetics, also referred to as SWEETS (Surrozen Wnt signal Enhancers Engineered for Tissue Specificity), are antibody-based molecules that enhance Wnt signaling by stabilizing Frizzled receptors on targeted cells.

About Surrozen
Surrozen is a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues and organs damaged by serious disease. Surrozen is designing tissuespecific antibodies that engage the body’s own biological repair mechanisms resulting in a broad pipeline of disease-specific therapies to help patients across multiple disease areas. For more information, please visit surrozen.com.

###

Investors/Partners:
Reza Afkhami
VP, Corporate Development and Strategy
Surrozen, Inc.
reza@surrozen.com

Surrozen Scientific Founder Roel Nusse, PhD Receives Prestigious Canada Gairdner International Award for Biomedical Research

Award recognizes Dr. Nusse’s seminal contributions to elucidating the mechanism and role of Wnt signaling

SOUTH SAN FRANCISCO, Calif., April 6, 2020 — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that one of its scientific founders, Dr. Roel Nusse, received the 2020 Canada Gairdner International Award for Biomedical Research for pioneering work on the Wnt signaling pathway and its importance in development, cancer and stem cells. The Canada Gairdner Foundation annually designates five outstanding biomedical scientists who have made original contributions to medicine resulting in an increased understanding of human biology and disease. Since 1957, 395 awards have been bestowed on laureates from 35 countries and of those awardees, 92 have gone on to receive Nobel Prizes.

Roel Nusse co-founded Surrozen, along with other leaders in Wnt biology, in 2016. Dr. Nusse is The Virginia and Daniel K. Ludwig Professor of Cancer Research, Professor & Chair, Department of Developmental Biology and Member, Institute for Stem Cell Biology and Regenerative Medicine, at the Stanford University School of Medicine. He is a Howard Hughes Medical Institute Investigator, a member of the US National Academy of Sciences, the American Academy of Arts & Sciences, the Royal Dutch Academy of Sciences and is a recipient of the Breakthrough Prize in Life Sciences (2017).

The Canada Gairdner Foundation cited a number of scientific contributions in announcing the award, such as the original discovery of Wnt made by Dr. Nusse together with Harold Varmus, a member of Surrozen’s Board of Directors and Scientific Advisory Board. The Foundation further noted:

Afterwards Dr. Nusse identified the Drosophila Wnt homolog as a key developmental gene, Wingless. Using Drosophila genetics, he established the function of betacatenin as a mediator of Wnt signaling and the Frizzleds as Wnt receptors (with Jeremy Nathans), thereby establishing core elements of what is now called the Wnt pathway. A major later accomplishment of his group was the first successful purification of active Wnt proteins, showing that they are lipid-modified and act as stem cell growth factors.

“All of us at Surrozen are proud of the fundamental contributions our scientific founders have made to the field of Wnt biology,” said Craig Parker, chief executive officer of Surrozen. “The Gairdner Award recognizes Dr. Nusse’s unique role at the epicenter of our understanding of Wnt biology. The discoveries that Dr. Nusse pioneered in understanding the mechanism and role of Wnt signaling serve as a foundation for the approach we are taking to harnessing the pathway for discovery of regenerative therapeutics.”

About Wnt Signaling
Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, including bone, liver, skin, intestine, lung, kidney, central nervous system, cochlea and others. Modulation of Wnt signaling pathways has potential for treatment of degenerative diseases and tissue injuries. There are 19 Wnt ligands (Wnts) in mammals, and they signal through Frizzled receptors (Fzds) 1-10 and LRP5 or 6, two families of receptors. Endogenous Wnts bind to multiple Fzds and are heavily modified post-translationally, making them difficult to manufacture consistently.

About Surrozen’s Proprietary Antibody Platforms and Harnessing Wnt Signaling
Since its founding in 2016, Surrozen has developed two proprietary platforms to selectively modulate the Wnt pathway for the potential treatment of injury and disease. Surrozen Wntmimetics, also referred to as SWAPs (Surrozen Wnt Signal Activating Proteins), are bi-specific fulllength human (IgG) antibodies that directly activate the canonical Wnt signaling pathway in target tissue. Surrozen R-spondin-mimetics, also referred to as SWEETS (Surrozen Wnt Signal Enhancer Engineered for Tissue Specificity), are uniquely engineered antibodies that stabilize Wnt receptors.

About Surrozen
Surrozen is a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues and organs damaged by serious disease. Surrozen is designing tissuespecific antibodies that engage the body’s own biological repair mechanisms resulting in a broad pipeline of disease-specific therapies to help patients across multiple disease areas. For more information, please visit surrozen.com.

###

Investors/Partners:
Reza Afkhami
VP, Corporate Development and Strategy
Surrozen, Inc.
reza@surrozen.com

Media:
Denise Powell
Red House Consulting
denise@redhousecomms.com

Surrozen to Present at Cowen and Company 40th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 2, 2020 – Surrozen, Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues, today announced that President & Chief Executive Officer, Craig Parker, will present at the Cowen and Company 40th Annual Health Care Conference in Boston, Massachusetts. The presentation will begin at 10:30 a.m. Eastern Standard Time on Wednesday, March 4, 2020.

Combining an understanding of Wnt pathway biology in specific disease settings with advanced antibody engineering techniques, Surrozen designs and develops tissue specific antibodies that have the potential to regenerate tissue in grave diseases including cirrhotic liver disease, inflammatory bowel disease, lung and airway diseases like IPF and COPD, neurodegenerative diseases and retinopathies.

About Surrozen’s Proprietary Antibody Platforms and Harnessing Wnt Signaling
The Wnt signaling pathway plays a critical role in stem cell maintenance, tissue regeneration and other important developmental processes. Since its founding in 2016, Surrozen has developed two proprietary platforms to selectively modulate the Wnt pathway for the potential treatment of injury and disease. Surrozen Wnt Signal Activators, also referred to as SWAPs (Surrozen Wnt Signal Activating Proteins), are bi-specific full-length human (IGg) antibodies that directly modulate the canonical Wnt signaling pathway in target tissue. Surrozen Wnt Protein Enhancers, also referred to as SWEETS (Surrozen Wnt Signal Enhancer Engineered for Tissue Specificity), are uniquely engineered antibodies that mimic the activity of endogenous R-spondin.

About Surrozen
Surrozen is a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues and organs damaged by serious disease. By designing tissue-specific antibodies that engage the body’s own biological tissue repair mechanisms, Surrozen is developing a broad pipeline of disease-specific therapies to help gravely ill patients across multiple disease areas. For more information, please visit surrozen.com.

###

Investors/Partners:
Reza Afkhami
VP, Corporate Development and Strategy
Surrozen, Inc.
reza@surrozen.com

Media:
Denise Powell
Red House Consulting
denise@redhousecomms.com

title

surrozen body